RC
VYNE icon

RegentAtlantic Capital’s VYNE Therapeutics VYNE Stock Holding History

RegentAtlantic Capital’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,393
Closed -$10K – 702
2022
Q2 		$10K Buy
+1,393
New +$11.7K ﹤0.01% 675
2021
Q1 		– Sell
-213
Closed -$24K – 558
2020
Q4 		$24K Hold
213
– – ﹤0.01% 499
2020
Q3 		$25K Hold
213
– – ﹤0.01% 487
2020
Q2 		$26K Buy
+213
New +$28.8K ﹤0.01% 473

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

RegentAtlantic Capital's VYNE Position: Q3 2022 in Review

RegentAtlantic Capital sold out of VYNE Therapeutics (VYNE) in Q3 2022, closing a stake of 1,393 shares — an estimated $10K sold.

RegentAtlantic Capital first reported a position in VYNE in Q2 2020 and held it in 4 quarters. The position peaked at $26K in Q2 2020. 41 funds tracked by Wall St. Rank hold VYNE as of Q3 2022.

  • RegentAtlantic Capital reported no remaining VYNE Therapeutics position as of Q3 2022 after selling out during the quarter.
  • RegentAtlantic Capital sold 1,393 VYNE Therapeutics shares in Q3 2022, an estimated $10K.
  • RegentAtlantic Capital first reported a position in VYNE Therapeutics in Q2 2020 and held it in 4 quarters.
  • RegentAtlantic Capital's VYNE Therapeutics position peaked at $26K in Q2 2020.
  • 41 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.